Thiazolidinedione Treatment Decreases Bone Mineral Density in Type 2 Diabetic Men
The DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Case-control studies of patients with fractures have found that subjects with diabetes have at least a twofold higher risk of fracture than subjects without diabetes (1), with an increased risk of hip, humerus, and foot fractures in elderly diabetic subjects (2–4). Risk factors that contribute to increased fracture in diabetic subjects include number of falls (5,6), insulin use (7,8), functional disability (9–11), diabetes duration (7,12), and poor vision (7). Recent studies report that older women and African Americans have higher incidence of osteoporotic fractures (13). In addition, lower bone strength (bone mineral density [BMD]) might be expected to increase risk for the development of osteoporosis and fracture. Type 2 diabetic patients are widely prescribed drugs called thiazolidinediones, which increase insulin sensitivity via activation of peroxisome proliferator–activated receptor (PPAR)-γ receptors. However, it is not known whether thiazolidinedione use has any effect on bone mass and thereby increases risk of fracture in type 2 diabetic patients. In animal studies, thiazolidinedione treatment was associated with bone loss in a mouse model (14,15), which was explained by possible imbalance in bone from increased apoptotic death of osteogenic cells and diminished bone formation (15), and also in ovariectomized rats (16). Other investigators did not find bone loss in troglitazone-treated mice (17). There is limited information on the effect of …
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Risk Factors for Hip Fracture in White Women
Cummings, S. R., Nevitt, M. C., Browner, W. S., Stone, K., Fox, K. M., Ensrud, K. E., Cauley, J., Black, D., & Vogt, T. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199503233321202 · Cited by 3,595
Yki-Järvinen, H. (2004) · New England Journal of Medicine · doi:10.1056/nejmra041001 · Cited by 1,830
Diabetes and incidence of functional disability in older women
Gregg, E. W., Mangione, C. M., Cauley, J. A., Thompson, T. J., Schwartz, A. V., Ensrud, K. E., Nevitt, M. C., & for the Study of Osteoporotic Fractures Research Group (2002) · Diabetes Care · doi:10.2337/diacare.25.1.61 · Cited by 333
Cited by
Long-term use of thiazolidinediones and fractures in type 2 diabetes: a meta-analysis
Loke, Y. K., Singh, S., & Furberg, C. D. (2009) · Canadian Medical Association Journal · doi:10.1503/cmaj.080486 · Cited by 551
Rosiglitazone-Associated Fractures in Type 2 Diabetes
Kahn, S. E., Zinman, B., Lachin, J. M., Haffner, S. M., Herman, W. H., Holman, R. R., Kravitz, B. G., Yu, D., Heise, M. A., Aftring, R. P., et al. (2008) · Diabetes Care · doi:10.2337/dc07-2270 · Cited by 537
Bone, sweet bone—osteoporotic fractures in diabetes mellitus
Hamann, C., Kirschner, S., Günther, K.-P., & Hofbauer, L. C. (2012) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2011.233 · Cited by 380
Use of Thiazolidinediones and Fracture Risk
Meier, C., Kraenzlin, M. E., Bodmer, M., Jick, S. S., Jick, H., & Meier, C. R. (2008) · Archives of Internal Medicine · doi:10.1001/archinte.168.8.820 · Cited by 355
Yamamoto, M., Yamaguchi, T., Yamauchi, M., Kaji, H., & Sugimoto, T. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.081207 · Cited by 327
PPARγ: a circadian transcription factor in adipogenesis and osteogenesis
Kawai, M., & Rosen, C. J. (2010) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.155 · Cited by 323
Giacomini, K. M., Krauss, R. M., Roden, D. M., Eichelbaum, M., Hayden, M. R., & Nakamura, Y. (2007) · Nature · doi:10.1038/446975a · Cited by 276
Dipeptidyl Peptidase-4 Inhibitors and Bone Fractures
Monami, M., Dicembrini, I., Antenore, A., & Mannucci, E. (2011) · Diabetes Care · doi:10.2337/dc11-1099 · Cited by 268
Lipodystrophy: pathophysiology and advances in treatment
Fiorenza, C. G., Chou, S. H., & Mantzoros, C. S. (2011) · Nature Reviews Endocrinology · doi:10.1038/nrendo.2010.199 · Cited by 255
How safe is the use of thiazolidinediones in clinical practice?
Rizos, C., Elisaf, M., Mikhailidis, D., & Liberopoulos, E. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330802597821 · Cited by 161
Osteoporosis after stroke: a review of the causes and potential treatments
Carda, S., Cisari, C., Invernizzi, M., & Bevilacqua, M. (2009) · Cerebrovascular Diseases · doi:10.1159/000226578 · Cited by 104
RetractedGrey, A., Bolland, M., Fenwick, S., Horne, A., Gamble, G., Drury, P. L., & Reid, I. R. (2014) · European Journal of Endocrinology · doi:10.1530/eje-13-0793 · Cited by 43
Metadata
- Authors
- Yaturu, S., Bryant, B., & Jain, S. K.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 2007-06-01
- Volume
- 30
- Issue
- 6
- Pages
- 1574-1576
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W2167397201
- Cited by
- 156
- References
- 3
- FWCI
- 23.05
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.